^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Rupp PA, Fouad GT, Egelston CA, Reifsteck CA, Olson SB, Knosp WM, Glanville RW, Thornburg KL, Robinson SW, Maslen CL (Jul 2002). "Identification, genomic organization and mRNA expression of CRELD1, the founding member of a unique family of matricellular proteins". Gene. 293 (1–2): 47–57. doi:10.1016/S0378-1119(02)00696-0. PMID12137942.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Ortiz JA, Castillo M, del Toro ED, et al. (2006). "The cysteine-rich with EGF-like domains 2 (CRELD2) protein interacts with the large cytoplasmic domain of human neuronal nicotinic acetylcholine receptor alpha4 and beta2 subunits". J. Neurochem. 95 (6): 1585–96. doi:10.1111/j.1471-4159.2005.03473.x. PMID16238698.
Maslen CL, Babcock D, Redig JK, et al. (2007). "CRELD2: gene mapping, alternate splicing, and comparative genomic identification of the promoter region". Gene. 382: 111–20. doi:10.1016/j.gene.2006.06.016. PMID16919896.